Oncoral multidisciplinary monitoring for adults taking oral anticancer medicines
Official title: PACOME (PAtient Cancer Oral MEdication) Cohort of Patients Treated With Oral Anticancer Drugs Benefiting From Oncoral Multidisciplinary Monitoring in Real Life: Predictive Factors and Safety of Treatments
Run by Hospices Civils de Lyon · NCT06317389 · Data updated 2026-11-12
This project will test whether Oncoral's city–hospital monitoring and patient questionnaires help spot safety problems and improve care for adults taking oral anticancer drugs as outpatients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Pierre-Bénite) |
| Status | Recruiting |
| Started | June 23, 2025 |
| Main results expected | July 2035 |
| Study ends | July 2037 |
| Registry record updated | September 3, 2025 |
| Trial ID | NCT06317389 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) scheduled to receive an oral anticancer drug who are enrolled in the Oncoral monitoring program and followed in pulmonology, dermatology, hematology, medical oncology, gastroenterology, or radiotherapy at Lyon-Sud, without major psychiatric disorder and not opposed to participation.
✕Probably not a fit
Patients in interventional clinical trials, institutionalized patients, those under legal protection measures, or patients not followed in the specified Lyon-Sud departments are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PACOME is an observational cohort of adult outpatients treated with oral anticancer drugs who are enrolled in the Oncoral multidisciplinary monitoring program at Lyon-Sud. Participants complete questionnaires while clinical and pharmacy teams collect real-life data on drug-related problems, dose changes, safety events, and healthcare use. The project analyzes predictive factors for medication-related problems and patterns of dose intensity and treatment modifications outside clinical trials. No experimental treatment is given—care is managed per usual practice within the Oncoral coordination model.
Why it matters
Potential benefit: If successful, this could reduce medication-related harms, help maintain appropriate dosing, and improve coordination of outpatient cancer care.
How similar studies have gone: Similar multidisciplinary outpatient medication‑monitoring programs, including the Oncoral initiative launched in 2014, have reported improved detection and management of drug-related problems, though large comparative outcome data remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged over 18 * eligible for treatment with oral anticancer drug (ATCO) (excluding clinical trial) in a cancer indication and whose treatment with an oral anticancer drug is scheduled * follow-up in one of the following departments at Lyon-Sud hospital: pulmonology, dermatology, hematology, medical oncology, gastroenterology or radiotherapy. * without a major psychiatric disorder likely to hinder the progress of the study, in the opinion of the investigator * participant in the ONCORAL monitoring program * Not having opposed participating in the study Exclusion Criteria: * in an institution * under legal protection measure
Where it's running
-
Groupement Hospitalier Sud - Unité de Pharmacie Clinique Oncologique
Pierre-Bénite, France Recruiting
Study contacts
- Study coordinator: Catherine RIOUFOL, Pr
- Email: catherine.rioufol@chu-lyon.fr
- Phone: 04 78 86 43 68
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.